Deaths by suicide and by substance use disorders have reached epidemic proportions, creating the tragic “perfect storm” of epidemics within a pandemic. A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized.
The global Covid-19 pandemic has further exposed and exacerbated the fractures within our healthcare and social delivery systems particularly with regard to behavioral health (mental health and substance use) conditions.
This is especially concerning given a Kaiser Family Foundation (KFF) report suggesting that a third of U.S. adults now report symptoms consistent with an anxiety and/or depressive disorder. More specifically, a KFF analysis of U.S. Census Bureau survey data published in June 2020 indicated 36.5% of U.S. adults reported anxiety or depressive disorder symptoms, a troubling increase from the already substantial statistic of 11% in 2019. Specific to the pandemic, a KFF poll reported that 53% of adults indicated their mental health has been negatively impacted due to worry and stress related to Covid-19. Attention has also been given to the impact of Covid-19 on healthcare professionals and first responders, who may be vulnerable to anxiety, depression, grief, substance abuse, and post-traumatic stress related to caring for patients and families impacted by Covid-19, as well as concerns regarding risks of infection for themselves and their families.
Also of grave concern is the potential for a dramatic increase in “deaths of despair”— deaths by suicide, alcohol, or other substance misuse commonly associated with the extreme distress resulting from natural disasters and pandemics. Studies have found that job loss, debt, and foreclosure increase the risk for suicidal thinking; indeed, the rates of suicide and the proportion of alcohol-involved suicides rose during the Great Recession of 2008-2009.
Recently, the U.S. Centers for Disease Control and Prevention (CDC) released its own findings detailing the damaging impact of the Covid-19 pandemic on mental health in vulnerable populations. Close to 11% of adults seriously considered suicide during June 2020, according to CDC data. In addition, the risk for suicidal ideation was heightened among respondents between ages 18 and 25 (25.5%), Hispanic respondents (18.6%), Black respondents (15.1%), unpaid adult caregivers (30.7%), and essential workers (21.7%).
Without rapid and robust intervention, it is estimated that an additional 75,000 lives could be lost in the United States alone to alcohol and drug misuse and suicide associated with Covid-19. As examples of this trend, Shelby County, Tennessee, saw 391 suspected overdoses and 58 deaths over a 1-month span in April and May, while Milwaukee and parts of Ohio are seeing opioid overdoses and deaths also spike significantly. In July, the American Medical Association (AMA) sounded the alarm about opioid overdoses, noting a rising number of reports from more than 35 states of increases in opioid-related mortality—particularly from illicitly manufactured fentanyl and fentanyl analogs. Also of note is the September, 2020 U.S. Food and Drug Administration (FDA) update to the Boxed Warning for benzodiazepines, often abused and misused with opioids.
Given the present epidemiologic climate, it is not surprising that addiction experts consider the Covid-19 pandemic a risk factor for substance abuse relapse, leading the New York Times to refer to this pandemic as “a national relapse trigger.” Anaha Ortiz, MD, who practices in Franklin County, which includes Columbus, Ohio, stated, “Covid-19 has showed us the vulnerabilities and deficiencies in our addiction services—in addition, it has increased the mental health needs of this population.”
In short, most Americans or someone they know has or will be impacted by behavioral health conditions associated with Covid-19 stressors, and some populations, such as those with pre-existing behavioral health conditions, marginalized communities of color, families living in poverty, and those previously traumatized by violence or natural disaster, may be particularly vulnerable to Covid-19 stressors. The practice of trauma-informed care has never been more imperative.
As the world continues to grapple with the Covid-19 pandemic, it is important to take a closer look at our nation’s health systems, integrated delivery networks and health plans, and the resulting re-prioritizations that have occurred in addressing behavioral health concerns during the pandemic. This article will share recently collected survey data on the shifting priorities of health plans and health systems pertaining to behavioral health conditions since the onset of Covid-19. The paper further offers some observations and suggestions for opportunities for plans, delivery systems, and pharmaceutical manufacturers to address these “epidemics within a pandemic.”
In April 2020, PRECISIONvalue used its RapidPulseTM tool to survey healthcare access decision makers. Objectives were to gain insights into the current and expected future impact of the Covid-19 pandemic on payers’ and health systems’ population health priorities and how these priorities are affecting administrative, care management, and population health practices during the Covid-19 pandemic. Included in the survey were questions about behavioral health conditions and relevant care management and population health practices. Respondents (N=30) represented health plans (n=16) and health systems (n=14) and comprised medical, pharmacy, quality, and population health directors, providing services for an estimated 95 million lives.
Not surprisingly, the majority of survey respondents (67%) reported that mental health conditions have risen in priority since the onset of Covid-19. However, an alarming 80% of respondents indicated that opioid conditions had decreased in priority since Covid-19 began. Taken together with the AMA’s report of increased opioid overdoses and with an historic 400,000 or more U.S. deaths since 1996 related to opioids, these statistics represent a clarion call for concerted action to address this epidemic within a pandemic. Further, since substance use disorders often co-occur with other behavioral health conditions (eg, anxiety, depression, bipolar disorder, schizophrenia), an approach that prioritizes integrated care for all behavioral health conditions (mental health and substance use) is imperative to promoting physical health, responsible health behavior, and resilience during a time of greatly heightened isolation and uncertainty.
Opportunities also exist during the pandemic for population health management collaboration among health plans, health systems, and pharmaceutical manufacturers. Survey results found that health plans and health systems indicated current or planned collaborations, or willingness to collaborate with pharmaceutical manufacturers on areas such as medication adherence management (87%), patient outreach/engagement (83%), and supporting quality performance (83%). These findings shine a strategic spotlight on opportunities for collaboration to better address the behavioral health epidemics within the pandemic and to direct resources to synergistically address concerns.
Healthcare delivery is experiencing a crisis of tremendous magnitude, and given that other conditions, notably infectious disease and respiratory conditions, have risen in priority since the onset of Covid-19, a not surprising result of an overburdened system is deprioritization of other chronic conditions, such as opioid use disorders. However, this is proving to be misguided, in light of the recent AMA brief regarding increases in opioid-related mortality, and the rise in mental health conditions, which will likely include an exacerbation or emergence of new substance use disorders. These circumstances present opportunities for stakeholders, such as plans, health systems, and pharmaceutical manufacturers to facilitate behavioral health recovery through focused, individual, and synergistic efforts. Potential opportunities for stakeholders to address these conditions arise through strategic focus upon 3 areas: access, analytics, and amplification.
Opportunities for Stakeholders
Although 76% of Americans think mental health is as important as physical health, lack of awareness of and limited care options, cost, stigma, and wait times all create barriers to behavioral healthcare. Below are actions stakeholders can consider to facilitate access now and beyond the Covid-19 pandemic.
Across the care continuum, predictive analytics have been found to contribute to population health management, improving costs and outcomes. Analytics have utility for management of substance abuse conditions and for suicide risk prediction, facilitating more targeted, efficient, and effective use of resources for at-risk patients.
Despite all the advances in behavioral health education and treatment, there is still a significant public stigma and even self-stigma around behavioral health issues. These stigmas can contribute to gaps in seeking medical care and resources and lead to negative outcomes, such as worsening mental health, substance abuse relapses, and potentially suicide. Below are steps stakeholders can take to amplify stigma-busting messages and boost support and coping skills.
The Covid-19 pandemic has further exposed the fragmentation of the American healthcare and social delivery systems, particularly relevant to care for mental health and substance use conditions. In the United States, deaths attributable to suicide and to substance use disorders exist as epidemics within the Covid-19 pandemic. Survey data suggest that overburdened health systems and health plans may be deprioritizing population health efforts to address opioid use disorders, while prioritizing care for mental health conditions, further straining a long-overtaxed mental health delivery system.
Yet, access to evidence-based behavioral healthcare is vital to advancing the resilience and responsible health behaviors required during the pandemic, necessitating the acceleration of behavioral and physical health integration. Multistakeholder, strategic focus upon the Three A’s—Access, Analytics, and Amplification—has the potential to effect better population health management for individuals with behavioral health conditions and comorbidities, both during the pandemic and beyond.
Maureen Hennessey PhD, CPCC, CPHQ, is senior VP and director of Value Transformation at PRECISIONvalue. Avi Mamidi PharmD, RPh is director of the North America Market Access at ResMed.